Psilocybin-assisted group therapy in patients with cancer diagnosed with a major depressive disorder

This Phase II, open-label trial (n=30) assessed psilocybin-assisted therapy (25mg) for patients with cancer and depression (MDD) with individual and group therapeutic support. The study reported no serious adverse events and suggested efficacy with a significant reduction in depression severity by week 8. Notably, 80% of participants had a sustained response, and 50% achieved full remission of depressive symptoms at week 1, maintained for eight weeks. The study highlights the safety and feasibility of psilocybin-assisted therapy in a group cohort.

Abstract of Psilocybin-assisted group therapy in patients with cancer diagnosed with a major depressive disorder

Background Depression is common in patients with cancer and is associated with lower treatment adherence and reduced quality of life. Antidepressants and psychotherapy have limited success in improving depression among patients with cancer. This study explored the safety, feasibility, and efficacy of psilocybin-assisted therapy in patients with cancer and major depressive disorder.

Methods This phase 2, open-label trial enrolled patients with curable and noncurable cancer and major depressive disorder at a single community oncology practice site. A single 25-mg dose of psilocybin was administered simultaneously to cohorts of three to four participants with individual (4.25 hours in 1:1 therapist-to-patient ratio) and group therapeutic support (3.75 hours) before, during, and after psilocybin administration. Outcomes included depression severity, anxiety, pain, demoralization, and disability.

Results Thirty participants completed the study. No psilocybin-related serious adverse events occurred; treatment-related adverse events (e.g., nausea, headache) were generally mild and expected. There were no laboratory or electrocardiogram abnormalities. No suicidality was reported. Efficacy was suggested with a robust reduction in depression severity scores from baseline to posttreatment of 19.1 points (95% CI, 22.3 to –16.0; p < .0001) by week 8. Eighty percent of participants demonstrated a sustained response to psilocybin treatment; 50% showed full remission of depressive symptoms at week 1, which was sustained for 8 weeks.

Conclusions Psilocybin-assisted therapy in group cohort administration was safe and feasible in patients with cancer and depression. Efficacy was suggested based on clinically meaningful reductions in depressive symptoms. The novel, group-oriented format, compact delivery time, community cancer center setting, and one-to-one therapist-to-patient ratio could also add to therapeutic gains and efficiency of administration.”

Authors: Manish Agrawal, William A. Richards, Yvan Beaussant, Sarah Shnayder, Rezvan Ameli, Kimberly Roddy, Norma Stevens, Brian B. Richards, Nick Schor, Heather Honstein, Betsy Jenkins, Mark Bates, Paul Thambi

Summary of Psilocybin-assisted group therapy in patients with cancer diagnosed with a major depressive disorder

Depression is one of the most common psychiatric disorders in patients with cancer, yet common treatments have limited success and have side effects and drug interactions that make their suitability uncertain.

Psilocybin is a serotonergic agonist that modulates neural networks to alter perception, affect, and ego function. It may also mediate improvement in patient well-being by providing an escape from negative and rigid cognitive patterns common in depressive states.

This study tested the safety, feasibility, tolerability, and efficacy of psilocybin-assisted therapy in a group setting for patients with cancer diagnosed with MDD.

To access this content, you must purchase one of the following memberships: Sprout Membership, Pro Membership, Pro Membership Unlimited, Business Membership or Business Membership Unlimited. The membership will give you access to exclusive data, including summaries of psychedelic research papers, extended company info, and our member-only visualisations. Save yourself multiple hours each week by accessing Blossom’s resource library.

Find this paper

Psilocybin-assisted group therapy in patients with cancer diagnosed with a major depressive disorder

https://doi.org/10.1002/cncr.35010

Paywall | Google Scholar | Backup | 🕊

Cite this paper (APA)

Agrawal, M., Richards, W., Beaussant, Y., Shnayder, S., Ameli, R., Roddy, K., ... & Thambi, P. (2023). Psilocybin-assisted group therapy in patients with cancer diagnosed with a major depressive disorder. Cancer.

Study details

Compounds studied
Psilocybin

Topics studied
Depression Palliative Care

Study characteristics
Original Open-Label

Participants
30 Humans

Institutes

Institutes associated with this publication

Sunstone Therapies
Sunstone Therapies is dedicated to the development and implementation of innovative therapies for individuals affected by cancer and other conditions.

Compound Details

The psychedelics given at which dose and how many times

Psilocybin 25 mg | 1x

Linked Research Papers

Notable research papers that build on or are influenced by this paper

Acceptability of psilocybin-assisted group therapy in patients with cancer and major depressive disorder: Qualitative analysis
This interview study (n=28) explored the acceptability of psilocybin-assisted group therapy in patients with cancer and depression (MDD) who were part of a clinical trial. Through semi-structured interviews, it found a generally positive view towards group therapy, highlighting its role in enhancing participants' safety, preparedness, connection, and belonging. The study identified key factors influencing acceptability, including the therapeutic framework's importance, the complementary nature of individual sessions, and the impact of group size and interaction structure.

Group psychedelic therapy: empirical estimates of cost-savings and improved access
This economic analysis (2023) from two psychedelic therapy trials (MDMA-PTSD & psilocybin-MDD) with group and individual therapy aims to assess clinician time, costs, and patient access. Group therapy demonstrated cost savings of 50.9% for MDMA-PTSD and 34.7% for psilocybin-MDD, potentially reducing the need for full-time equivalent clinicians by 6,711 for MDMA-PTSD and 1,159 for psilocybin-MDD in the U.S., leading to projected savings of up to $10.3 billion and $2.0 billion, respectively, over ten years. Adopting group therapy protocols is suggested to enhance efficiency, reduce costs, and address the shortage of trained clinicians, thereby improving access to psychedelic-assisted therapies.

Linked Clinical Trial

The Safety and Efficacy of Psilocybin in Cancer Patients With Major Depressive Disorder
This is a Phase II, single-center, fixed dose, open label trial to explore the safety, tolerability and efficacy of a 25mg dose of psilocybin in cancer patients with MDD.